Daniel Rittirsch

Dr. Daniel Rittirsch


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2008 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
DRDaniel Rittirsch
Daniel Rittirsch
MHMarkus S Huber-Lang
Markus S Huber-Lang
MFMichael A Flierl
Michael A Flierl
Peter A WardPeter A Ward
Peter A Ward

1 October 2008 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
DRDaniel Rittirsch
Daniel Rittirsch
MFMichael A. Flierl
Michael A. Flierl
Peter A WardPeter A Ward
Peter A Ward

21 May 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MHMarkus Huber-Lang
Markus Huber-Lang
JSJ Vidya Sarma
J Vidya Sarma
FZFiras S Zetoune
Firas S Zetoune
DRDaniel Rittirsch
Daniel Rittirsch
TNThomas A Neff
Thomas A Neff
PWPeter A Ward
Peter A Ward

1 November 2010 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
UAUmme Amara
Umme Amara
MFMichael A Flierl
Michael A Flierl
DRDaniel Rittirsch
Daniel Rittirsch
AKAndreas Klos
Andreas Klos
HCHui Chen
Hui Chen
MHMarkus Huber-Lang
Markus Huber-Lang
The complement system as well as the coagulation system has fundamental clinical implications in the context of life-threatening tissue injury and inflammation. Associations between both cascades have been proposed, but the precise molecular mechanisms remain unknown. The current study reports multiple links for various factors of the coagulation and fibrinolysis cascades with the central complement components C3 and C5 in vitro and ex vivo. Thrombin, human coagulation factors (F) XIa, Xa, and IXa, and plasmin were all found to effectively cleave C3 and C5. Mass spectrometric analyses identified the cleavage products as C3a and C5a, displaying identical molecular weights as the native anaphylatoxins C3a and C5a. Cleavage products also exhibited robust chemoattraction of human mast cells and neutrophils, respectively. Enzymatic activity for C3 cleavage by the investigated clotting and fibrinolysis factors is defined in the following order: FXa > plasmin > thrombin > FIXa > FXIa > control. Furthermore, FXa-induced cleavage of C3 was significantly suppressed in the presence of the selective FXa inhibitors fondaparinux and enoxaparin in a concentration-dependent manner. Addition of FXa to human serum or plasma activated complement ex vivo, represented by the generation of C3a, C5a, and the terminal complement complex, and decreased complement hemolytic serum activity that defines exact serum concentration that results in complement-mediated lysis of 50% of sensitized sheep erythrocytes. Furthermore, in plasma from patients with multiple injuries (n = 12), a very early appearance and correlation of coagulation (thrombin–antithrombin complexes) and the complement activation product C5a was found. The present data suggest that coagulation/fibrinolysis proteases may act as natural C3 and C5 convertases, generating biologically active anaphylatoxins, linking both cascades via multiple direct interactions in terms of a complex serine protease system.

30 September 2007 in Nature
Verified
Journal Article
Closed access
MFMichael A. Flierl
Michael A. Flierl
DRDaniel Rittirsch
Daniel Rittirsch
BNBrian A. Nadeau
Brian A. Nadeau
ACAnthony J. Chen
Anthony J. Chen
JSJ. Vidya Sarma
J. Vidya Sarma
Peter A WardPeter A Ward
Peter A Ward

4 May 2008 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DRDaniel Rittirsch
Daniel Rittirsch
MFMichael A Flierl
Michael A Flierl
BNBrian A Nadeau
Brian A Nadeau
DDDanielle E Day
Danielle E Day
MHMarkus Huber-Lang
Markus Huber-Lang
Peter A WardPeter A Ward
Peter A Ward